Literature DB >> 21853228

Intravitreous VEGF-A in eyes with massive vitreous hemorrhage.

Makoto Shirasawa1, Noboru Arimura, Hiroki Otsuka, Shozo Sonoda, Teruto Hashiguchi, Taiji Sakamoto.   

Abstract

PURPOSE/
BACKGROUND: Although vascular endothelial growth factor (VEGF) is abundant in serum, the intraocular concentration of VEGF in eyes with massive vitreous hemorrhage (VH) is not well-known. The present study was conducted to elucidate the effects of a massive VH on intravitreous VEGF concentration.
METHODS: Vitreous samples were obtained during vitrectomy: 12 samples from eyes with epiretinal membrane without diabetic retinopathy (DR), and nine samples from massive VH with no DR, such as age-related macular degeneration, rhegmatogenous VH, Terson's syndrome and macro-aneurysm rupture. Twelve samples were obtained from proliferative DR. VEGF was measured with an enzyme-linked immunosorbent assay (ELISA). Samples incubated with or without heparin were also examined for the release of VEGF binding to the vitreous body. The localization of VEGF and type II collagen in the vitreous was evaluated from immunohistochemistry.
RESULTS: The concentration of VEGF was significantly higher in eyes with proliferative DR (821 ± 949 pg/ml) than in non-DR with massive VH (2.75 ± 7.5 pg/ml, P < 0.01, chi-square test) or non-DR with no VH (less than detectable level, P < 0.01, chi-square test) There was no statistically significant difference between eyes with massive VH and non-diabetic eyes without VH. Treatment with heparin did not significantly affect the concentration of vitreous VEGF. VEGF was localized mainly in the clot from the results of an immunohistochemical analysis.
CONCLUSIONS: Even with a massive VH, diffusible VEGF does not increase significantly in the liquid phase and is principally present in a clot. VH alone should not be an indication for vitrectomy from the point of view of VEGF-related pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21853228     DOI: 10.1007/s00417-011-1795-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  Opticin binds to heparan and chondroitin sulfate proteoglycans.

Authors:  V John Hindson; John T Gallagher; Willi Halfter; Paul N Bishop
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-12       Impact factor: 4.799

2.  Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.

Authors:  R Möhle; D Green; M A Moore; R L Nachman; S Rafii
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

3.  Bioactivity of the vascular endothelial growth factor trapped in fibrin clots: production of IL-6 and IL-8 in monocytes by fibrin clots.

Authors:  K Tezono; K P Sarker; H Kikuchi; M Nasu; I Kitajima; I Maruyama
Journal:  Haemostasis       Date:  2001 Mar-Apr

4.  Immunohistochemical localization of low density lipoprotein receptor-related protein 1 and alpha(2)-Macroglobulin in retinal and choroidal tissue of proliferative retinopathies.

Authors:  P F Barcelona; J D Luna; G A Chiabrando; C P Juarez; I A Bhutto; T Baba; D S McLeod; M C Sánchez; G A Lutty
Journal:  Exp Eye Res       Date:  2010-06-01       Impact factor: 3.467

5.  Stromal cell-derived factor-1 is essential for photoreceptor cell protection in retinal detachment.

Authors:  Hiroki Otsuka; Noboru Arimura; Shozo Sonoda; Makoto Nakamura; Teruto Hashiguchi; Ikuro Maruyama; Shintaro Nakao; Ali Hafezi-Moghadam; Taiji Sakamoto
Journal:  Am J Pathol       Date:  2010-10-01       Impact factor: 4.307

6.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

Authors:  J E Park; G A Keller; N Ferrara
Journal:  Mol Biol Cell       Date:  1993-12       Impact factor: 4.138

7.  Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.

Authors:  Dominik Krilleke; Andrea DeErkenez; William Schubert; Indrajit Giri; Gregory S Robinson; Yin-Shan Ng; David T Shima
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

8.  Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.

Authors:  Noboru Arimura; Hiroki Otsuka; Keita Yamakiri; Yasushi Sonoda; Shintaro Nakao; Yoshihiro Noda; Teruto Hashiguchi; Ikuro Maruyama; Taiji Sakamoto
Journal:  Ophthalmology       Date:  2009-05       Impact factor: 12.079

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

Review 10.  Platelets, petechiae, and preservation of the vascular wall.

Authors:  Ralph L Nachman; Shahin Rafii
Journal:  N Engl J Med       Date:  2008-09-18       Impact factor: 91.245

View more
  3 in total

1.  Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Ghulam Mohammad; Mohd Imtiaz Nawaz; Mohammad Mairaj Siddiquei; Kathleen Van den Eynde; Ahmed Mousa; Gert De Hertogh; Ghislain Opdenakker
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

2.  Serial bevacizumab injections and laser photocoagulation for macular edema associated with a retinal artery macroaneurysm.

Authors:  Ella H Leung; Ashvini K Reddy; Anil S Vedula; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-04-04

3.  Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy.

Authors:  Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Ghulam Mohammad; Mohammad Mairaj Siddiquei; Kaiser Alam; Ahmed Mousa; Ghislain Opdenakker
Journal:  Lipids Health Dis       Date:  2014-12-11       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.